Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1474527
This article is part of the Research Topic Post-Transcriptional Modifications in Cancer Immunity and Immunotherapy View all articles

Alternative Splicing Regulation by Tumor Suppressing Subtransferable Candidate 4: A Pathway to Tumor Suppression

Provisionally accepted
Duanwu Zhang Duanwu Zhang *Haiping Zhao Haiping Zhao Nana Wu Nana Wu Gaigai Wei Gaigai Wei Huiling Zhang Huiling Zhang Tingrong Ren Tingrong Ren Jingjing Yi Jingjing Yi Yuqi Zhang Yuqi Zhang Zixi Wang Zixi Wang Yihan Wang Yihan Wang Zhihan Guo Zhihan Guo
  • Fudan University, Shanghai, China

The final, formatted version of the article will be published soon.

    RNA splicing is a crucial posttranscriptional process that governs gene expression, and abnormalities in alternative splicing contribute to various diseases, including cancer.Tumor suppressing subtransferable candidate 4 (TSSC4), a known tumor suppressor, has been identified as part of the U5 small nuclear ribonucleoprotein (snRNP), which promotes tri-snRNP biogenesis. However, the precise effects of TSSC4 on alternative splicing regulation and its impact on tumor growth remain unclear. To explore the link between splicing modulation and tumor suppression driven by TSSC4, we conducted transcriptome sequencing (RNA-seq) in TSSC4-knockout and wild-type HeLa cells. Our analysis of the RNA-seq data revealed that TSSC4 deficiency in HeLa cells leads to widespread alterations in splicing patterns and gene expression. Notably, using multiple cancer cell lines, including TSSC4-knockout A549 cells and TSSC4-knockdown PANC-1, MDA-MB-231, and MCF-7 cells, we confirmed that the loss of TSSC4 induces abnormal alternative splicing and dysregulation of tumor-associated genes, particularly several oncogenes. These findings underscore the critical role of TSSC4 in regulating RNA splicing and reveal a novel mechanism of TSSC4-mediated tumor suppression.

    Keywords: TSSC4, Alternative Splicing, Splicing, Gene Expression, tumorigenesis, Cancer Progression, oncogene

    Received: 01 Aug 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Zhang, Zhao, Wu, Wei, Zhang, Ren, Yi, Zhang, Wang, Wang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Duanwu Zhang, Fudan University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.